Korean J Med.  2017 Apr;92(2):124-141. 10.3904/kjm.2017.92.2.124.

Korean Treatment Guidelines for Metastatic Prostate Cancer Developed by the Korean Association for Clinical Oncology

Affiliations
  • 1Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
  • 2Department Hematology/Oncology, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Daegu, Korea.
  • 3Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
  • 4Division of Hematology/Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
  • 5Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • 6Division of Hematology/Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
  • 7Division of Hematology/Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, Korea.
  • 8Division of Medical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Busan, Korea.
  • 9Division of Hematology/Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 10Department of Internal Medicine, Dong-A University Hospital, Busan, Korea.
  • 11Division of Hematology/Oncology, Department of Internal Medicine, Daegu Fatima Hospital, Daegu, Korea.
  • 12Department of Internal Medicine, School of Medicine Chungnam National University, Daejeon, Korea.
  • 13Division of Hematology/Oncology, Department of Internal Medicine, Yonsei Univeristy Wonju College of Medicine, Wonju, Korea.
  • 14Departmen of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jaelyun@amc.seoul.kr

Abstract

The management of advanced prostate cancer has evolved rapidly. Androgen deprivation therapy, via surgical or medical castration, is the first-line therapy for hormone-naïve metastatic prostate cancer. For approximately a decade, docetaxel-based chemotherapy was the only approved agent to show a survival benefit for castration-resistant prostate cancer. However, over the last 5 years, significant advances in the field have led to the approval of several new agents with different mechanisms of action, such as the new androgen pathway inhibitors abiraterone and enzalutamide, a new cytotoxic agent, cabazitaxel, and new bone-seeking agents such as radium-223, which have all been associated with improved quality of life and pain palliation and an increase in survival. However, there has been no Korean treatment guideline for metastatic prostate cancer which is developed based on thorough search for relevant articles, including recently developed agents, and adequate review and assessment of evidences, and thus, a guideline adequate for domestic circumstance is eagerly needed. Experts from the Genitourinary Oncology Committee of the Korea Cancer Study Group developed clinical recommendations for the treatment of metastatic prostate cancer based on 19 key questions. The Korean Association for Clinical Oncology, the Korean Prostate Society, the Korean Urological Oncology Society, and the Korean Society of Pathologists reviewed and endorsed the guidelines. These are the first Korean treatment guidelines developed specifically for metastatic prostate cancer.

Keyword

Prostate cancer; Drug therapy; Metastasis; Guideline

MeSH Terms

Castration
Drug Therapy
Korea
Medical Oncology*
Neoplasm Metastasis
Prostate*
Prostatic Neoplasms*
Quality of Life
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error